Elite Journal of Laboratory Medicine. Volume 1 issue 1(2023), Pp. 13-27 https://epjournals.com/journals/EJLM

Hemochromatosis and HIV: Two Conditions, One Challenge

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Hemochromatosis and HIV represent two distinct yet interconnected medical conditions, each posing unique challenges to disease management. Hemochromatosis is characterized by excessive iron accumulation, while HIV infection results in immune dysfunction and increased susceptibility to infections. The coexistence of hemochromatosis and HIV presents complex clinical scenarios where iron overload may exacerbate HIV-related complications and vice versa. This review explores the epidemiology, clinical features, pathophysiology, diagnosis, and management strategies for hemochromatosis in individuals living with HIV. A multidisciplinary approach involving collaboration between infectious disease specialists, hematologists, and hepatologists is essential for optimizing outcomes in this population. Further research is needed to elucidate the optimal diagnostic and therapeutic strategies for managing hemochromatosis in individuals living with HIV, ultimately improving outcomes and quality of life.

Keywords*: Hemochromatosis, HIV, Iron overload, Co-morbidities, Disease management, Therapeutic interventions*

Introduction

Hemochromatosis and HIV represent two distinct yet intersecting medical conditions, each presenting unique challenges to disease management. Hemochromatosis, an inherited disorder of iron metabolism, is characterized by excessive iron absorption leading to iron overload and multi-organ damage. In contrast, HIV infection is a chronic viral illness characterized by immune dysfunction and heightened susceptibility to opportunistic infections. Despite their differences, the coexistence of hemochromatosis and HIV presents complex clinical scenarios where the interplay between iron overload and immune dysregulation may influence disease progression and

Citation: Obeagu EI. Hemochromatosis and HIV: Two Conditions, One Challenge. Elite Journal of Laboratory Medicine, 2023; 1(1): 13-27

therapeutic outcomes. The epidemiology of hemochromatosis and HIV reflects their distinct genetic and infectious etiologies, respectively. Hemochromatosis is one of the most common genetic disorders worldwide, particularly prevalent in individuals of Northern European descent, with a prevalence of approximately 1 in 200 individuals. In contrast, HIV infection affects over 38 million people globally, with a disproportionate burden in sub-Saharan Africa and other resource-limited settings. While hemochromatosis typically manifests in adults between the ages of 40 and 60 years, HIV can affect individuals of all ages, with a peak incidence in young adults.[1-15]

Clinical features of hemochromatosis and HIV vary widely but may overlap, posing challenges in diagnosis and management. Hemochromatosis may present with nonspecific symptoms such as fatigue, joint pain, hepatomegaly, and diabetes mellitus, while HIV infection can manifest with acute retroviral syndrome, immunodeficiency, and AIDS-defining illnesses. The coexistence of these conditions complicates the clinical picture, as symptoms of iron overload may mimic HIV-related complications, and vice versa, necessitating careful evaluation and differential diagnosis. The pathophysiology of hemochromatosis involves mutations in genes regulating iron homeostasis, particularly the HFE gene, leading to increased intestinal iron absorption and subsequent iron overload. Conversely, HIV infection is characterized by immune activation, chronic inflammation, and dysregulation of cytokine signaling pathways, resulting in progressive immune dysfunction and increased susceptibility to infections. The interplay between hemochromatosis and HIV is complex, with evidence suggesting bidirectional interactions where iron overload may exacerbate HIV replication and immune activation, while HIV-induced inflammation may further dysregulate iron metabolism.[16-30]

Diagnosis and screening for hemochromatosis in individuals with HIV require careful consideration of clinical features, laboratory parameters, and genetic testing. Screening for hemochromatosis should be considered in high-risk populations, including individuals of Northern European descent and those with a family history of the condition. Laboratory evaluation typically includes serum iron studies, transferrin saturation, ferritin levels, and genetic testing for HFE mutations. Differential diagnosis of iron overload in the context of HIV-related liver disease and opportunistic infections is essential for appropriate management. Management strategies for hemochromatosis in individuals with HIV involve a multidisciplinary approach aimed at reducing iron burden, optimizing antiretroviral therapy, and addressing co-morbidities. Therapeutic interventions may include phlebotomy to remove excess iron, iron chelation therapy in cases of severe iron overload, and nutritional counseling to promote overall health. Collaboration between infectious disease specialists, hematologists, and hepatologists is essential for optimizing outcomes and quality of life in individuals living with both hemochromatosis and HIV.[31-40]

Epidemiology and Clinical Features

Hemochromatosis and HIV present distinct epidemiological profiles and clinical features, each contributing to the complexity of their coexistence and management. Hemochromatosis is primarily a genetic disorder, with the majority of cases attributed to mutations in the HFE gene, particularly the C282Y and H63D variants. These mutations disrupt the normal regulation of iron

absorption, leading to excessive iron accumulation in tissues. Hemochromatosis is most commonly observed in individuals of Northern European descent, with a prevalence of approximately 1 in 200 individuals in this population. While hereditary hemochromatosis is the most well-known form of the disorder, secondary hemochromatosis can also occur secondary to conditions such as chronic liver disease, excessive alcohol consumption, and repeated blood transfusions. Clinical features of hemochromatosis vary depending on the stage of the disease and the extent of iron accumulation. In the early stages, patients may remain asymptomatic or present with nonspecific symptoms such as fatigue, joint pain, and abdominal discomfort. As iron overload progresses, symptoms may become more pronounced and include hepatomegaly, cirrhosis, diabetes mellitus, skin pigmentation changes (bronze or slate-gray skin), cardiac abnormalities (cardiomyopathy, arrhythmias), and endocrine dysfunction (hypogonadism, hypothyroidism). In severe cases, hemochromatosis can lead to life-threatening complications such as liver failure, heart failure, and hepatocellular carcinoma.[41-60]

In contrast, HIV infection is a global pandemic affecting millions of individuals worldwide, with a disproportionate burden in sub-Saharan Africa and other resource-limited settings. HIV is primarily transmitted through unprotected sexual intercourse, sharing contaminated needles, and perinatal transmission from mother to child. The clinical course of HIV infection is characterized by progressive immune dysfunction, leading to increased susceptibility to opportunistic infections, malignancies, and other complications. Acute HIV infection may manifest as a flu-like illness (acute retroviral syndrome) characterized by fever, rash, lymphadenopathy, and pharyngitis. Without treatment, HIV infection progresses to chronic HIV disease, characterized by a decline in CD4+ T-cell count and the development of AIDS-defining illnesses, including opportunistic infections (e.g., Pneumocystis jirovecii pneumonia, cryptococcal meningitis) and AIDS-related malignancies (e.g., Kaposi sarcoma, non-Hodgkin lymphoma). The coexistence of hemochromatosis and HIV presents unique challenges in diagnosis and management. Patients with HIV and iron overload may present with overlapping symptoms, such as fatigue and hepatomegaly, necessitating a comprehensive evaluation to differentiate between HIV-related complications and iron overload-related manifestations. Additionally, the presence of hemochromatosis may impact the natural history and progression of HIV infection, potentially influencing treatment outcomes and disease prognosis. Thus, a thorough understanding of the epidemiology and clinical features of both conditions is essential for optimizing the diagnosis and management of individuals living with hemochromatosis and HIV.[61-80]

Pathophysiology and Mechanisms

The pathophysiology of hemochromatosis and HIV involves distinct yet interconnected mechanisms that contribute to the complexity of their coexistence and impact on disease progression. Hemochromatosis is primarily characterized by dysregulation of iron homeostasis, resulting in excessive iron absorption and accumulation in various tissues. The majority of cases of hereditary hemochromatosis are attributed to mutations in the HFE gene, particularly the C282Y and H63D variants. These mutations disrupt the normal interaction between the HFE protein and transferrin receptor 1 (TfR1), leading to decreased hepcidin synthesis and increased iron uptake

by enterocytes. Consequently, iron accumulates in tissues such as the liver, pancreas, heart, and joints, causing cellular damage and multi-organ dysfunction. In secondary hemochromatosis, iron overload may result from conditions such as chronic liver disease, excessive alcohol consumption, or repeated blood transfusions, leading to increased intestinal iron absorption or impaired iron utilization. In contrast, HIV infection is characterized by progressive immune dysfunction and dysregulation of the host immune response. Following initial infection, HIV targets CD4+ T lymphocytes, macrophages, and dendritic cells, leading to direct viral replication and cytopathic effects. HIV-induced immune activation triggers a cascade of inflammatory responses, including the release of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which contribute to chronic immune activation and systemic inflammation. Persistent immune activation and dysregulation of cytokine signaling pathways lead to accelerated apoptosis of CD4+ T cells, depletion of immune effector cells, and progressive immunodeficiency. Additionally, HIV-associated microbial translocation, gut dysbiosis, and disruption of mucosal integrity further contribute to systemic immune activation and inflammation.[81-90]

The interplay between hemochromatosis and HIV is complex and bidirectional, with evidence suggesting potential interactions that may influence disease progression and therapeutic outcomes. Iron overload has been shown to exacerbate HIV replication and immune activation by promoting viral entry, replication, and pro-inflammatory cytokine production. Elevated iron levels may also impair immune function and reduce the efficacy of antiretroviral therapy, leading to suboptimal virologic control and increased risk of HIV-related complications. Conversely, HIV-induced inflammation and immune dysregulation may further perturb iron metabolism and exacerbate iron overload through mechanisms such as hepcidin suppression and increased iron uptake by macrophages. Understanding the pathophysiology and mechanisms underlying the coexistence of hemochromatosis and HIV is crucial for optimizing disease management and therapeutic interventions. Further research is needed to elucidate the complex interactions between iron metabolism and immune function in individuals living with both conditions, ultimately improving outcomes and quality of life for this population.[91-95]

Diagnosis and Screening

The diagnosis and screening of hemochromatosis in individuals living with HIV require a comprehensive approach that considers clinical manifestations, laboratory parameters, and genetic testing. Given the potential overlap of symptoms between hemochromatosis and HIV-related complications, a high index of suspicion is necessary for early detection and diagnosis. Clinical features suggestive of hemochromatosis may include fatigue, joint pain, hepatomegaly, abnormal liver function tests, and evidence of end-organ damage such as diabetes mellitus or cardiomyopathy. However, these symptoms may be nonspecific and may also occur in the context of HIV-related conditions, necessitating careful evaluation and differential diagnosis. Laboratory evaluation plays a crucial role in the diagnosis and screening of hemochromatosis in individuals with HIV. Serum iron studies, including serum iron concentration, transferrin saturation (TSAT), and serum ferritin levels, are commonly used to assess iron status and identify evidence of iron overload. Elevated serum iron levels, elevated TSAT (>45%), and markedly elevated serum

ferritin levels (>300 ng/mL in men, >200 ng/mL in women) are suggestive of iron overload and warrant further evaluation.[96-100]

Genetic testing for mutations in the HFE gene is considered the gold standard for confirming the diagnosis of hereditary hemochromatosis. The most common mutations associated with hereditary hemochromatosis are the C282Y and H63D variants in the HFE gene. Genetic testing can be performed using polymerase chain reaction (PCR) techniques to identify specific HFE gene mutations. However, it is important to note that not all individuals with hemochromatosis will carry HFE gene mutations, particularly in cases of non-HFE-associated hemochromatosis. Screening for hemochromatosis in individuals living with HIV should be considered in high-risk populations, including individuals of Northern European descent and those with a family history of the condition. Routine screening with serum iron studies, including serum ferritin and transferrin saturation, may be warranted in individuals with suggestive symptoms or evidence of abnormal liver function tests. Genetic testing for HFE gene mutations should be considered in individuals with elevated iron indices suggestive of hereditary hemochromatosis. It is important to recognize that the presence of HIV infection may impact the interpretation of iron studies and genetic testing results. HIV-related inflammation and immune activation may lead to alterations in iron metabolism, potentially confounding the interpretation of iron indices. Additionally, the presence of HIV-related liver disease or opportunistic infections may contribute to abnormalities in liver function tests and further complicate the diagnostic evaluation.[101-102]

Management Strategies

The management of hemochromatosis in individuals living with HIV involves a multidisciplinary approach aimed at reducing iron burden, optimizing antiretroviral therapy, and addressing co-morbidities associated with both conditions. Phlebotomy, or the removal of excess iron-rich blood, represents the primary treatment modality for hemochromatosis. Regular phlebotomy sessions are performed to reduce iron stores and maintain serum ferritin levels within the target range. In individuals with HIV, phlebotomy may be beneficial in reducing iron overload and mitigating associated complications, such as liver fibrosis and cardiomyopathy. However, careful monitoring of hematologic parameters and iron status is essential to prevent iatrogenic anemia and ensure therapeutic efficacy. Iron chelation therapy may be considered in individuals with severe iron overload or contraindications to phlebotomy. Chelating agents such as deferoxamine, deferiprone, and deferasirox bind to excess iron molecules and facilitate their excretion from the body. While data on the use of iron chelators in individuals with HIV-associated iron overload are limited, these agents may be considered in select cases where phlebotomy is not feasible or contraindicated. Close monitoring for adverse effects, including gastrointestinal disturbances and renal toxicity, is essential when using iron chelation therapy in this population.[103-104]

Optimizing antiretroviral therapy (ART) is crucial for managing HIV infection and minimizing the impact of HIV-related complications on iron metabolism. Selection of ART regimens should take into account potential drug interactions with iron chelators or other medications used to manage hemochromatosis. Additionally, monitoring for drug-related toxicities, including

mitochondrial dysfunction and hepatotoxicity, is essential for optimizing treatment outcomes and minimizing adverse effects on iron metabolism. Nutritional interventions play a vital role in managing hemochromatosis and optimizing overall health in individuals living with HIV. Encouraging a balanced diet rich in fruits, vegetables, and lean proteins while limiting iron-rich foods and alcohol consumption can help prevent further iron accumulation and mitigate associated complications. Nutritional supplementation, including vitamins and minerals, may be indicated in cases of malnutrition or micronutrient deficiencies commonly observed in individuals with HIV. Addressing co-morbidities associated with both hemochromatosis and HIV is integral to optimizing outcomes in this population. Close monitoring and management of liver function, cardiovascular health, and endocrine function are essential components of comprehensive care. Screening for complications such as liver fibrosis, diabetes mellitus, and cardiomyopathy should be performed regularly to detect early signs of disease progression and facilitate timely intervention. Lifestyle modifications, including regular physical activity, weight management, and smoking cessation, are important for optimizing overall health and reducing the risk of co-morbidities in individuals living with hemochromatosis and HIV. Counseling on safe sex practices and harm reduction strategies, including needle exchange programs, is essential to prevent transmission of HIV and other bloodborne infections.[105-108]

Conclusion

The coexistence of hemochromatosis and HIV presents a unique challenge in disease management, necessitating a comprehensive and multidisciplinary approach. Hemochromatosis, characterized by excessive iron accumulation, and HIV, a chronic viral infection, have distinct yet intersecting pathophysiological mechanisms that influence disease progression and therapeutic outcomes. The diagnosis of hemochromatosis in individuals with HIV requires careful consideration of clinical features, laboratory parameters, and genetic testing. Screening for hemochromatosis should be performed in high-risk populations, with close attention to potential confounding factors such as HIV-related inflammation and immune activation. Genetic testing for HFE gene mutations is essential for confirming the diagnosis of hereditary hemochromatosis and guiding therapeutic decisions. The management of hemochromatosis in individuals with HIV involves reducing iron burden through phlebotomy or iron chelation therapy, optimizing antiretroviral therapy, addressing co-morbidities, and promoting healthy lifestyle behaviors. Close collaboration between infectious disease specialists, hematologists, hepatologists, and nutritionists is essential for tailoring treatment strategies to the individual needs of each patient.

References

1. Devi P, Khan A, Chattopadhyay P, Mehta P, Sahni S, Sharma S, Pandey R. Co-infections as modulators of disease outcome: minor players or major players? Frontiers in microbiology. 2021; 12:664386.
2. Zanella I, Focà E, Degli-Antoni M, Castelli F, Quiros-Roldan E. An HIV elite controller patient carrying the homozygous H63D variant in the homeostatic iron regulator gene: A case report. Medicine. 2021;100(45): e27732.

Citation: Obeagu EI. Hemochromatosis and HIV: Two Conditions, One Challenge. Elite Journal of Laboratory Medicine, 2023; 1(1): 13-27

3. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019 ;11(3):200.
4. Paparizos V, Kourkounti S. HIV Infection and AIDS: The Present Status of Antiretroviral Therapy. InEuropean Handbook of Dermatological Treatments 2023; 429-442. Cham: Springer International Publishing.
5. Cai CW, Sereti I. Residual immune dysfunction under antiretroviral therapy. InSeminars in immunology 2021; 51: 101471. Academic Press.
6. Sundermann EE, Erlandson KM, Pope CN, Rubtsova A, Montoya J, Moore AA, Marzolini C, O'Brien KK, Pahwa S, Payne BA, Rubin LH. Current challenges and solutions in research and clinical care of older persons living with HIV: Findings presented at the 9th international workshop on HIV and aging. AIDS research and human retroviruses. 2019;35(11-12):985-98.
7. Ahmed D, Roy D, Cassol E. Examining relationships between metabolism and persistent inflammation in HIV patients on antiretroviral therapy. Mediators of inflammation. 2018.
8. Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. Aids. 2008;22: S7-12.
9. Obeagu EI. Comparative Study of Serum Iron and Hemoglobin Levels of Cord Blood of Normal Neonates and that of Maternal Blood in Federal Medical Centre Owerri. Journal of Clinical and Laboratory Research. 2021;4(1):2768-0487.
10. Obeagu EI, Aneke J, Okafor CN, Essein UC, Ochei KC, Obeagu GU. Assessment of Serum Iron Status of Malnourished Infants in Umuahia, Abia State, Nigeria. Sch J App Med Sci. 2016; 4:4384-7.
11. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471.
12. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
13. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
14. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
15. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
16. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.

Citation: Obeagu EI. Hemochromatosis and HIV: Two Conditions, One Challenge. Elite Journal of Laboratory Medicine, 2023; 1(1): 13-27

17. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
18. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
19. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
20. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
21. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
22. Obeagu EI, Oshim IO, Ochei KC, Obeagu GU. Iron and blood donation: A Review. Int. J. Curr. Res. Med. Sci. 2016;2(10):16-48.
23. Obeagu EI, Obeagu GU, Emeonye OP, Jakheng SP. An Upadte on Interleukin 6 And Iron Status of Volleyball Players. Madonna University journal of Medicine and Health Sciences. 2022;2(2):41-74.
24. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.
25. Obeagu EI, Anierobi CC, Eze GC, Chukwueze CM, Makonyonga RD, Amadi NM, Hassan R. Evaluation of Plasma Levels of Interleukin 6 and Iron Status of Volleyball Players in a Nigerian University. Journal of Advances in Medical and Pharmaceutical Sciences. 2022;24(6):18-23.
26. Obeagu EI, Obeagu GU, Guevara ME, Okafor CJ, Bot YS, Eze GC, Amadi NM, Jakheng EW, Uwakwe OS. Evaluation of Plasma Levels of Interleukin 6 and Iron of Volleyball Players Based on Heights and Weight of a Nigerian University Students. Asian Journal of Medicine and Health. 2022;20(10):147-152.
27. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
29. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-

OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.

30. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
31. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
32. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
33. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
34. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
35. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
36. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
37. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005

38. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
39. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
40. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
41. Obeagu E, Felix CE, MTB O, Chikodili UM, Nchekwubedi C1S, Chinedum OK. Studies on some cytokines, CD4, iron status, hepcidin and some haematological parameters in pulmonary tuberculosis patients based on duration of treatment in Southeast, Nigeria. African Journal of Biological Sciences. 2021;3(1):146-156.
42. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021;33(27A):36-43.
43. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
44. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-18.
45. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138.
46. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
47. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
48. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
49. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-

knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf

50. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
51. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
52. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
53. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
54. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
55. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
56. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
57. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
58. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A

PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
59. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
60. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
61. Obeagu EI, Nwazu ME, Obeagu GU. Evaluation of plasma levels of interleukin 6 and iron status based on sleeping patterns of students in a Nigerian University. Int. J. Curr. Res. Med. Sci. 2022;8(9):1-6.
62. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences. 2022;2(1):218-234.
63. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
64. Obeagu EI, Babar Q. Recent advances in understanding of Haemochromatosis: A burning issue of life. Int. J. Curr. Res. Med. Sci. 2021;7(7):23-28.
65. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. Int. J. Curr. Res. Med. Sci. 2018;4(10):42-48.
66. Edward Henry SI, Obeagu EI. Assessment of the Serum Iron Status of Preeclampsia Subjects in Aba, Abia State. Elite Journal of Haematology. 2024;2(1):10-18.
67. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
68. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
69. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
70. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.

Citation: Obeagu EI. Hemochromatosis and HIV: Two Conditions, One Challenge. Elite Journal of Laboratory Medicine, 2023; 1(1): 13-27

71. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
72. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
73. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
74. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
75. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
76. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
77. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
78. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
79. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
80. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
81. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
82. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.

Citation: Obeagu EI. Hemochromatosis and HIV: Two Conditions, One Challenge. Elite Journal of Laboratory Medicine, 2023; 1(1): 13-27

83. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
84. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
85. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
86. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
87. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
88. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
89. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
90. Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. Elite Journal of Health Science, 2023; 1(1):1-11
91. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Shielding Infants from HIV Transmission. Elite Journal of Health Science, 2023; 1(1):12-22
92. Obeagu EI, Obeagu GU. Protecting Generations: Early Infant Diagnosis's Role in Preventing HIV Spread. Elite Journal of Public Health, 2023; 1 (1): 1-11
93. Obeagu EI, Obeagu GU. Securing Health: The Role of Early Infant Diagnosis in Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 12-22
94. Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 23-33
95. Obeagu EI, Obeagu GU. From Classroom to Home: Strengthening the Continuum of Sickle Cell Disease Knowledge. Elite Journal of Health Science, 2023; 1(1):23-29
96. Obeagu EI, Obeagu GU. Incorporating Sickle Cell Disease Curriculum in Schools: An Effective Approach. Elite Journal of Health Science, 2023; 1(1):30-36
97. Obeagu EI, Obeagu GU. Community Leaders as Educators: Mobilizing for Sickle Cell Disease Reduction. Elite Journal of Health Science, 2023; 1(1):37-43
98. Obeagu EI, Obeagu GU. Peer-to-Peer Learning Networks: Sickle Cell Disease Education Among Adolescents. Elite Journal of Public Health, 2023; 1 (1): 34-41

99. Obeagu EI, Obeagu GU. From Awareness to Action: Encouraging Adolescent Engagement in Sickle Cell Disease Prevention. Elite Journal of Public Health, 2023; 1 (1): 42-50
100. Obeagu EI, Obeagu GU. The Vital Role of Antioxidants in Enhancing Fertility and Pregnancy Success: A Review. Elite Journal of Nursing and Health Science, 2023; 1(1):1-12
101. Obeagu EI, Obeagu GU. Harnessing the Power of Antioxidant-Rich Diet for Preconception Health: A Review. Elite Journal of Health Science, 2023; 1(1):1-13
102. Obeagu EI. Unraveling Diagnostic Challenges of Aplastic Anemia in the Context of HIV: A Review. Elite Journal of Nursing and Health Science, 2023; 1(1):13-23
103. Obeagu EI. **I**mmunological Insights into Aplastic Anemia within the Context of HIV: Unraveling the Complex Interplay. Elite Journal of Health Science, 2023; 1(1):14-24
104. Obeagu EI. Treatment Strategies for Aplastic Anemia in HIV: Current Approaches and Future Directions. Elite Journal of Laboratory Medicine, 2023; 1(1): 1-12
105. Hackl L, Itzkowitz L, Koso-Thomas M, Moorthy D, Owino V, Pachón H, Stoffel N, Zimmerman M, Raiten D, Loechl C, Datta-Mitra A. Approaches to Address the Anemia Challenge. The Journal of Nutrition. 2023;153(Suppl 1).
106. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2012;1823(9):1434-1443.
107. Ibrahim SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, Wolf JL, Sundaram SS. Liver diseases in the perinatal period: interactions between mother and infant. Hepatology. 2020;71(4):1474
108. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV, 2023; 1(1): 15-28